Enlivex Therapeutics (ENLV) Projected to Post Earnings on Friday

Enlivex Therapeutics (NASDAQ:ENLV) is expected to post its quarterly earnings results before the market opens on Friday, April 4th. Analysts expect Enlivex Therapeutics to post earnings of ($0.16) per share for the quarter.

Enlivex Therapeutics Price Performance

NASDAQ ENLV opened at $1.01 on Friday. The company has a fifty day moving average price of $1.10 and a 200-day moving average price of $1.24. The firm has a market cap of $21.62 million, a price-to-earnings ratio of -1.03 and a beta of 1.11. Enlivex Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.59.

Analysts Set New Price Targets

ENLV has been the subject of several analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $13.00 price objective on shares of Enlivex Therapeutics in a research note on Monday, March 3rd. HC Wainwright increased their price target on Enlivex Therapeutics from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.